JP2023552583A - 置換されたピラゾロピペリジンカルボン酸類 - Google Patents

置換されたピラゾロピペリジンカルボン酸類 Download PDF

Info

Publication number
JP2023552583A
JP2023552583A JP2023535063A JP2023535063A JP2023552583A JP 2023552583 A JP2023552583 A JP 2023552583A JP 2023535063 A JP2023535063 A JP 2023535063A JP 2023535063 A JP2023535063 A JP 2023535063A JP 2023552583 A JP2023552583 A JP 2023552583A
Authority
JP
Japan
Prior art keywords
compounds
compound
diseases
acid
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023535063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552583A5 (https=
JPWO2022122914A5 (https=
Inventor
ヴァカロプロス，アレクサンドロス
コリン・クレペリン，マリー・ピエール
オルテガ・ヘルナンデス，ヌリア
ディースカウ，アンドレ
ブルタダキス・アラピニス，メリッサ
キャンディッシュ，リサ
ステルフェルド，ティモ
マタール，イルカ
ホフマイスター，ルーカス・ハドソン
サンドナー，ピーター
ヴンダー，フランク
ディーツ，リサ
ウェブスター，ロバート・アラン
シュメック，カーステン
モンドリッツキ，トーマス
Original Assignee
バイエル・アクチエンゲゼルシヤフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイエル・アクチエンゲゼルシヤフト filed Critical バイエル・アクチエンゲゼルシヤフト
Publication of JP2023552583A publication Critical patent/JP2023552583A/ja
Publication of JP2023552583A5 publication Critical patent/JP2023552583A5/ja
Publication of JPWO2022122914A5 publication Critical patent/JPWO2022122914A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023535063A 2020-12-10 2021-12-09 置換されたピラゾロピペリジンカルボン酸類 Pending JP2023552583A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20213020 2020-12-10
EP20213020.9 2020-12-10
PCT/EP2021/084987 WO2022122914A1 (en) 2020-12-10 2021-12-09 Substituted pyrazolo piperidine carboxylic acids

Publications (3)

Publication Number Publication Date
JP2023552583A true JP2023552583A (ja) 2023-12-18
JP2023552583A5 JP2023552583A5 (https=) 2024-12-10
JPWO2022122914A5 JPWO2022122914A5 (https=) 2024-12-10

Family

ID=73793025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535063A Pending JP2023552583A (ja) 2020-12-10 2021-12-09 置換されたピラゾロピペリジンカルボン酸類

Country Status (31)

Country Link
US (1) US20240051935A1 (https=)
EP (1) EP4259617B1 (https=)
JP (1) JP2023552583A (https=)
KR (1) KR20230118144A (https=)
CN (1) CN116710439A (https=)
AR (1) AR124297A1 (https=)
AU (1) AU2021393988A1 (https=)
CA (1) CA3204495A1 (https=)
CL (1) CL2023001632A1 (https=)
CO (1) CO2023007335A2 (https=)
CR (1) CR20230242A (https=)
DK (1) DK4259617T3 (https=)
DO (1) DOP2023000115A (https=)
EC (1) ECSP23040828A (https=)
ES (1) ES2997117T3 (https=)
FI (1) FI4259617T3 (https=)
GE (2) GEAP202316287A (https=)
HR (1) HRP20241543T1 (https=)
HU (1) HUE069255T2 (https=)
IL (1) IL303296A (https=)
JO (1) JOP20230132A1 (https=)
LT (1) LT4259617T (https=)
MX (1) MX2023006903A (https=)
PE (1) PE20231501A1 (https=)
PL (1) PL4259617T3 (https=)
PT (1) PT4259617T (https=)
RS (1) RS66294B1 (https=)
SA (1) SA523441083B1 (https=)
SI (1) SI4259617T1 (https=)
TW (1) TW202237589A (https=)
WO (1) WO2022122914A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4011873A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
EP4011874A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
EP4536205A1 (en) 2022-06-09 2025-04-16 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women
JP2026504406A (ja) * 2023-01-31 2026-02-05 インビボサイエンシーズ インコーポレイテッド 駆出率保持型心不全（ＨＦｐＥＦ）の治療に関するシステムおよび方法
WO2025067414A1 (zh) * 2023-09-27 2025-04-03 海思科医药集团股份有限公司 吡唑羧酸衍生物及其在医药上的应用
WO2025162280A1 (zh) * 2024-01-30 2025-08-07 海思科医药集团股份有限公司 吡唑羧酸衍生物及其在医药上的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012058132A1 (en) * 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2015095515A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma
JP2015527394A (ja) * 2012-09-07 2015-09-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化因子としてのアルコキシピラゾール
WO2022122916A1 (en) * 2020-12-10 2022-06-16 Bayer Aktiengesellschaft Substituted pyrazolyl piperidine carboxylic acids
JP2023514928A (ja) * 2020-12-10 2023-04-12 バイエル・アクチエンゲゼルシヤフト 眼科疾患の治療のためのｓＧＣ活性化剤の使用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
KR20100059952A (ko) * 2007-09-06 2010-06-04 머크 샤프 앤드 돔 코포레이션 가용성 구아닐레이트 사이클라제 활성제
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
EA023221B1 (ru) 2010-02-27 2016-05-31 Байер Интеллектуэль Проперти Гмбх СВЯЗАННЫЕ БИС-АРИЛЬНЫЕ АРИЛ-ТРИАЗОЛОНЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, ИХ ПРИМЕНЕНИЕ, ЛЕКАРСТВЕННОЕ СРЕДСТВО НА ИХ ОСНОВЕ И ДВОЙНОЙ АНТАГОНИСТ V1a/V2-РЕЦЕПТОРОВ
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
PE20130779A1 (es) 2010-07-09 2013-06-21 Bayer Ip Gmbh Pirimidinas y triazinas condensadas y su uso
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
UA121558C2 (uk) 2014-11-03 2020-06-25 Баєр Фарма Актіенгезеллшафт Гідроксіалкілзаміщені фенілтриазольні похідні та їх застосування
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012058132A1 (en) * 2010-10-28 2012-05-03 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
JP2015527394A (ja) * 2012-09-07 2015-09-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化因子としてのアルコキシピラゾール
WO2015095515A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma
WO2022122916A1 (en) * 2020-12-10 2022-06-16 Bayer Aktiengesellschaft Substituted pyrazolyl piperidine carboxylic acids
JP2023514928A (ja) * 2020-12-10 2023-04-12 バイエル・アクチエンゲゼルシヤフト 眼科疾患の治療のためのｓＧＣ活性化剤の使用

Also Published As

Publication number Publication date
GEAP202316287A (en) 2023-09-11
ECSP23040828A (es) 2023-07-31
HUE069255T2 (hu) 2025-02-28
SI4259617T1 (sl) 2025-02-28
PL4259617T3 (pl) 2025-03-17
FI4259617T3 (fi) 2024-11-27
DK4259617T3 (da) 2024-12-09
CN116710439A (zh) 2023-09-05
SA523441083B1 (ar) 2025-06-12
JOP20230132A1 (ar) 2023-06-08
TW202237589A (zh) 2022-10-01
MX2023006903A (es) 2023-06-26
GEP20247649B (en) 2024-07-25
CL2023001632A1 (es) 2023-11-10
AU2021393988A1 (en) 2023-06-22
AU2021393988A9 (en) 2024-09-19
ES2997117T3 (en) 2025-02-14
CO2023007335A2 (es) 2023-06-09
CR20230242A (es) 2023-07-19
PT4259617T (pt) 2024-12-05
PE20231501A1 (es) 2023-09-26
IL303296A (en) 2023-07-01
AR124297A1 (es) 2023-03-15
US20240051935A1 (en) 2024-02-15
LT4259617T (lt) 2024-12-10
EP4259617B1 (en) 2024-10-23
EP4259617A1 (en) 2023-10-18
RS66294B1 (sr) 2025-01-31
WO2022122914A1 (en) 2022-06-16
HRP20241543T1 (hr) 2025-01-03
CA3204495A1 (en) 2022-06-16
KR20230118144A (ko) 2023-08-10
DOP2023000115A (es) 2023-07-16

Similar Documents

Publication Publication Date Title
JP7451700B2 (ja) 置換されたピラゾロピペリジンカルボン酸類
EP4259617B1 (en) Substituted pyrazolo piperidine carboxylic acids
EP4259616B1 (en) Substituted pyrazolo piperidine carboxylic acids
US20240109864A1 (en) Substituted pyrazolyl piperidine carboxylic acids
EA047635B1 (ru) Замещенные пиразолопиперидинкарбоновые кислоты
HK40073287A (en) Substituted pyrazolo piperidine carboxylic acids
EA049460B1 (ru) Замещенные пиразолопиперидинкарбоновые кислоты
BR122025013946A2 (pt) Ácidos carboxílicos de pirazolo piperidina substituídos, seus processos de preparação
HK40091213A (zh) 取代的吡唑并哌啶羧酸
HK40118186A (zh) 取代的吡唑并哌啶羧酸
BR122025013926A2 (pt) Ácidos carboxílicos de pirazolo piperidina substituídos, seu processo de preparação e medicamento
HK40073287B (zh) 取代的吡唑并哌啶羧酸

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251225

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20260113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260421